These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 28893836)

  • 1. Immunotherapy against endocrine malignancies: immune checkpoint inhibitors lead the way.
    Cunha LL; Marcello MA; Rocha-Santos V; Ward LS
    Endocr Relat Cancer; 2017 Dec; 24(12):T261-T281. PubMed ID: 28893836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives for immunotherapy in endocrine cancer.
    Latteyer S; Tiedje V; Schilling B; Führer D
    Endocr Relat Cancer; 2016 Oct; 23(10):R469-84. PubMed ID: 27485460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New targets and therapeutic approaches for endocrine malignancies.
    Fassnacht M; Kreissl MC; Weismann D; Allolio B
    Pharmacol Ther; 2009 Jul; 123(1):117-41. PubMed ID: 19374919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibition in ovarian cancer.
    Hamanishi J; Mandai M; Konishi I
    Int Immunol; 2016 Jul; 28(7):339-48. PubMed ID: 27055470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors.
    Sheng J; Srivastava S; Sanghavi K; Lu Z; Schmidt BJ; Bello A; Gupta M
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S26-S42. PubMed ID: 28921644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.
    Nagai H; Muto M
    Int J Clin Oncol; 2018 Jun; 23(3):410-420. PubMed ID: 29516216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunotherapy in lung cancer: New concepts].
    Goubet AG; Livartowski A; Romano E
    Rev Mal Respir; 2018 Jun; 35(6):642-651. PubMed ID: 29941206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma.
    Kimbara S; Kondo S
    World J Gastroenterol; 2016 Sep; 22(33):7440-52. PubMed ID: 27672267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings.
    Wang GX; Kurra V; Gainor JF; Sullivan RJ; Flaherty KT; Lee SI; Fintelmann FJ
    Radiographics; 2017; 37(7):2132-2144. PubMed ID: 29131763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on New Therapies With Immune Checkpoint Inhibitors.
    Peterson JJ; Steele-Moses SK
    Clin J Oncol Nurs; 2016 Aug; 20(4):405-10. PubMed ID: 27441513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine side effects induced by immune checkpoint inhibitors.
    Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers.
    Schott M
    Endocr Relat Cancer; 2006 Sep; 13(3):779-95. PubMed ID: 16954430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies.
    Tsirigotis P; Savani BN; Nagler A
    Ann Med; 2016 Sep; 48(6):428-439. PubMed ID: 27224873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Renaissance of immuno-oncology for urological tumors : Current status].
    Grimm MO; Winkler Y; Fetter I; Oppel-Heuchel H
    Urologe A; 2016 May; 55(5):621-6. PubMed ID: 27119960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors.
    De Felice F; Marchetti C; Palaia I; Musio D; Muzii L; Tombolini V; Panici PB
    J Immunol Res; 2015; 2015():191832. PubMed ID: 26236750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer.
    Bauer C; Kühnemuth B; Duewell P; Ormanns S; Gress T; Schnurr M
    Cancer Lett; 2016 Oct; 381(1):259-68. PubMed ID: 26968250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. THERAPY OF ENDOCRINE DISEASE Immunotherapy of advanced thyroid cancer: from bench to bedside.
    Moretti S; Menicali E; Nucci N; Guzzetti M; Morelli S; Puxeddu E
    Eur J Endocrinol; 2020 Aug; 183(2):R41-R55. PubMed ID: 32449696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma.
    Lucca LE; Hafler DA
    Immunol Rev; 2017 Mar; 276(1):9-25. PubMed ID: 28258696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.